- Home
- / Isracann Biosciences
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Isracann Biosciences financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$0
2024-10-29
Market Capitalization
$2 M
2024-10-29
CreditSafe Score
?
Score changed on Jun 11, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| CAD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 |
|---|---|---|---|---|---|
| Revenue | 1.1M | 1.7M | 19.0K | ||
| Gross profit | 1.1M | 1.7M | 339.0K | 19.0K | |
| Gross profit margin, % | 100.0% | 100.0% | 100.0% | ||
| Operating expense total | 6.9M | 6.7M | 9.8M | 3.1M | 891.0K |
| Depreciation and amortization | 1.6M | 4.9M | 347.0K | 20.7M | 42.0K |
| EBITDA | (5.8M) | (5.0M) | (9.5M) | (2.9M) | (2.4M) |
| EBITDA margin, % | -521.8% | -295.8% | -15142.1% | ||
| EBIT | (7.4M) | (10.0M) | (9.8M) | (23.6M) | (2.4M) |
| EBIT margin, % | -665.0% | -585.3% | -124052.6% | ||
| Interest income | 63.0K | 140.0K | 75.0K | 94.0K | |
| Interest expense | 120.0K | 139.0K | 14.0K | ||
| Pre tax profit | (7.5M) | (9.9M) | (24.3M) | (25.1M) | (4.7M) |
| Income tax expense | 1.0K | 31.0K | |||
| Net Income | (7.5M) | (9.9M) | (24.3M) | (25.2M) | (4.7M) |